Paper Details

  1. Home
  2. Paper Details

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Author: AhnJin-Seok, BeckJoseph T, BraitehFadi, EdenfieldWilliam Jeffrey, EsakiTaito, Gambacorti-PasseriniCarlo, HoribeKeizo, HuangHuiqiang, KimTae Min, OrlovSergey, PaoliniJolanda, SelaruPaulina, ShiYuankai, TamuraKenji, TaylorMatthew, Van TineBrian A, WuShang-Ju, ZhangLi

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Crizotinib, a drug that targets the ALK, MET, and ROS1 proteins, showed strong and durable activity in patients with ALK-positive lymphoma and inflammatory myofibroblastic tumors (IMTs). In a phase 1b study, 53% of lymphoma patients and 67% of IMT patients achieved a response, with a median treatment duration of almost 3 years. The most common side effects were diarrhea and vision disorders, mainly grade 1.
Paper Details　
Original Abstract of the Article :
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell ly...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947833/

データ提供：米国国立医学図書館（NLM）

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study

Crizotinib, a targeted therapy used to treat certain types of cancers, has shown promise in treating ALK-positive non-small-cell lung cancer (NSCLC). This study delves into the potential of crizotinib for treating other types of ALK-positive tumors, exploring its long-term safety and efficacy in a broader range of patients.

Expanding the Horizons of Targeted Therapy

The study reveals that crizotinib demonstrates significant and durable activity in ALK-positive lymphomas and inflammatory myofibroblastic tumors (IMTs). This suggests that crizotinib may be a valuable treatment option for a wider range of cancers beyond NSCLC. The study also highlights the long-term safety of crizotinib, even with prolonged treatment.

Harnessing the Power of Precision Medicine

This research highlights the promise of precision medicine, a new approach to cancer treatment that targets specific genetic alterations. The findings underscore the importance of identifying ALK-positive tumors and tailoring treatment accordingly, potentially leading to more effective and personalized care for patients.

Dr.Camel's Conclusion

This study, like a desert explorer discovering new and valuable resources, expands our understanding of crizotinib's potential. It suggests that this targeted therapy can be a powerful weapon against a wider range of cancers, offering hope for patients with ALK-positive tumors. The study also underscores the importance of continued research in precision medicine, paving the way for more effective and personalized treatments in the future.

Date :
  1. Date Completed 2019-05-15
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

29352732

DOI: Digital Object Identifier

PMC5947833

Related Literature

Article Analysis
・Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.